verified Open-Science Translational Biology • Global Research Hub

Precision Therapeutics for β-Sarcoglycanopathy

The central scientific repository for Limb-Girdle Muscular Dystrophy R4 (LGMD 2E / SGCB deficiency): connecting human clinical genetics, AAV clinical pipelines, in vivo base editing, and cytoprotective peptide biophysics.

vaccines Gene Therapy & CRISPR shield 4-Layer Peptide Shield radar Live Research Radar

Abstract 3D molecular visualization of the human sarcoglycan complex spanning a lipid bilayer

biotech Cryo-EM / Structural Model

Molecular Architecture NM_000232.5

Transmembrane Sarcoglycan Core Tetramer

Stoichiometric assembly (α, β, γ, δ) anchoring the dystrophin-glycoprotein complex and dissipating contractile shear strain.

info

Patient & Clinical Community Transparency Charter

Limb-Girdle Muscular Dystrophy R4 (LGMD 2E) is a progressive, life-altering autosomal recessive disease. Families navigating this diagnosis deserve absolute scientific truth, rigorous peer-reviewed evidence, and an unvarnished assessment of translational realities:

warning Regulatory Reality

There are currently no FDA, EMA, or TGA-approved disease-modifying or curative therapeutics for LGMD R4. Standard of care remains supportive multidisciplinary management, physical therapy, and serial cardiac/respiratory surveillance.

biotech AAV Gene Therapy Horizon

Recombinant AAV gene replacement vectors (e.g., investigational SRP-9003 / AAVrh74.MHCK7.hSGCB) targeting full-length cDNA delivery are undergoing active clinical trial evaluation (e.g., NCT03652246 & NCT06246513).

shield Investigational Peptide Shield

The 4-layer cytoprotective peptide architecture detailed on this platform is an open-science research blueprint engineered to address downstream mechanical micro-tears, calpain proteolysis, and mitochondrial decay. It does not replace the missing gene.

*Disclaimer: This repository is compiled for medical scientists, neuromuscular neurologists, geneticists, and custom peptide CRO synthesis chemists. It does not constitute individual medical advice. Never initiate or alter clinical management without consultation with a qualified neuromuscular clinical specialist.

apps Platform Architecture

Explore the 6 Research Modules

Navigate into specialized deep-dive sections covering molecular genetics, gene therapy pipelines, custom peptide specifications, and live scientific intelligence.

dna

Molecular Pathology & Genetics

The "House of Cards" sarcoglycan assembly hierarchy, ERAD degradation, and exact molecular analysis of the compound heterozygous Ser114Phe and Tyr184* variants.

View Genetic Mapping arrow_forward

biotech

Gene Therapy & CRISPR Horizons

SRP-9003 Phase 3 EMERGENE biopsy data, AAVrh74 vector biology, in vivo Adenine Base Editing (ABE) for Ser114Phe, and non-viral SORT LNPs / eVLPs.

View Gene Therapy & Editing arrow_forward

shield

4-Layer Cytoprotective Shield

Chemical sequences, RCM hydrocarbon stapling, cyclic calpastatin, SS-31, CRO SPPS synthesis criteria (≥98% purity), and synchronized dosing protocols.

Explore Peptide Chemistry arrow_forward

clinical_notes

Clinical Protocol & Biomarkers

Quantitative 5-tier biomarker matrix: Serum CK, Cardiac MRI (T1/ECV), hs-cTnI, TGF-β1, urinary β2-microglobulin, and NSAA motor batteries.

View Monitoring Framework arrow_forward

radar

Live Research Radar & News

Real-time scientific news feeds connecting to live NCBI PubMed papers, active ClinicalTrials.gov registries, and curated deep-dive clinical reports.

Open Live Radar Feed arrow_forward

description

Dossiers & Literature

Download the complete 4-page Clinical Dossier (MED-SGCB-2026-CLIN) and benchmark report (BIO-DMD-2026-TR8), plus 10 verified PubMed citations.

Download Technical PDFs arrow_forward

view_timeline Development Hierarchy

The 4-Tier Translational Spectrum

Grounding scientific hope in measurable biological realities: how clinical supportive care, AAV gene replacement, precision base editing, and cytoprotective shields intersect.

Tier 1 • Active Standard

Clinical Supportive Care

Non-eccentric physical therapy, annual cardiac MRI with LGE, early ACEi/ARBs for heart strain, and nocturnal respiratory surveillance.

View Protocol arrow_forward

Tier 2 • Active Trials

AAV Gene Replacement

SRP-9003 Phase 3 EMERGENE (NCT06246513) met primary Day-60 biopsy endpoint (+43.4% PPF in ambulatory, +23.9% in non-ambulatory cohorts).

View Gene Therapy arrow_forward

Tier 3 • Pre-Clinical

Base & Prime Editing

Adenine Base Editing (ABE) for the c.341C>T transition mutation (scarless repair without DSBs) and Prime Editing for the c.552T>G stop codon.

View CRISPR arrow_forward

Tier 4 • CRO Synthesis

4-Layer Peptide Shield

Engineered sarcolemmal sealant, stapled NBD, cyclic calpastatin, and SS-31 to intercept downstream necrosis and preserve cardiac cristae.

View Peptide Shield arrow_forward

terminal Technical Documentation

Download the Complete Clinical & CRO Synthesis Dossiers

Full-length 4-page clinical translation report detailing SGCB genetics, ERAD trafficking, calpain cascades, synchronized dosing regimens, and CRO synthesis quality specifications (≥98.0% purity).

download Download Clinical PDF download Download Reference PDF